Cancer Lipid Metabolism Confers Antiangiogenic Drug ResistanceHideki Iwamoto, Yihai Cao, Mitsuhiko Abe et al.|Cell Metabolism|2018Cited by 305
Treatment and the prognosis of hepatocellular carcinoma in AsiaTakuji Torimura, Hideki Iwamoto|Liver International|2021Cited by 144
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)Dan Nakano, Takuji Torimura, Takumi Kawaguchi et al.|PLoS ONE|2020Cited by 86
High expression of <scp>CD</scp>44v9 and <scp>xCT</scp> in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazineFumitaka Wada, Takuji Torimura, Hironori Koga et al.|Cancer Science|2018Cited by 83
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective StudyShigeo Shimose, Takuji Torimura, Hideya Suga et al.|Cancers|2020Cited by 78